All orders placed by 2pm EST will be shipped same day Free Shipping Over $150 Gift With Every Order All orders placed by 2pm EST will be shipped same day Free Shipping Over $150 Gift With Every Order

CJC-157 + Ipamorelin

Categories:

CJC-157 + Ipamorelin Preloaded Pen is a dual-peptide research formulation combining a GHRH analog and a GHSR agonist. Studied for its potential synergistic effects on growth hormone axis signaling and IGF-1 pathway research in controlled laboratory environments. For research use only. Not for human or animal consumption.

$149.99

⚠️ RESEARCH USE ONLY

This product is for R&D purposes only and is not approved for human or veterinary use.

CJC-157 + Ipamorelin Preloaded Pen: Dual-Pathway Growth Hormone Axis Research Peptides

CJC-157 + Ipamorelin is a dual-peptide research formulation supplied in a preloaded laboratory pen format to support standardized handling within controlled experimental environments. This combination brings together a growth hormone–releasing hormone (GHRH) analog and a growth hormone secretagogue receptor (GHSR) agonist, both widely studied in endocrine research models.

The pairing of these two peptides has generated research interest due to their complementary mechanisms of action within the growth hormone (GH) regulatory axis. This formulation is intended exclusively for laboratory and academic investigation.

Research Context

CJC-157 is a synthetic GHRH analog engineered to enhance stability and prolong biological activity compared to endogenous GHRH. It has been examined in research settings for its influence on pituitary-mediated GH secretion and downstream insulin-like growth factor-1 (IGF-1) signaling.

Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist that mimics ghrelin signaling without significantly influencing cortisol or prolactin pathways in experimental models. In laboratory studies, Ipamorelin has been evaluated for its role in modulating pulsatile GH release via GHSR activation.

Research Overview

When examined together, CJC-157 and Ipamorelin are studied for their potential synergistic effects within the GH/IGF-1 signaling cascade. Their combined activity has been investigated in the following research areas:

  • Endocrine Axis Research – Evaluation of hypothalamic–pituitary signaling interactions.
  • Growth Hormone Pulsatility Models – Study of regulated GH secretion dynamics.
  • IGF-1 Pathway Investigation – Examination of downstream anabolic and cellular signaling pathways.
  • Metabolic Regulation Studies – Assessment of lipid metabolism and glucose homeostasis signaling.
  • Body Composition Research Models – Exploration of lean tissue and adipose regulatory mechanisms in controlled settings.

Preloaded Research Delivery Format

This product is supplied in a preloaded research pen format to promote precision handling and minimize variability during laboratory protocols. The delivery format is designed strictly for academic and experimental research environments and does not imply clinical or therapeutic use.

Important Compliance Notice

This product is intended solely for laboratory research purposes. CJC-157 and Ipamorelin have not been evaluated or approved for therapeutic, diagnostic, or cosmetic applications in humans or animals.

All research must comply with institutional policies, regulatory requirements, and ethical standards. Proper storage and handling procedures are required to maintain stability and experimental integrity.

For research use only. Not for human or animal consumption.

Related Products

Age Verification!

*By continuing, you confirm eligibility and legal compliance.